Published in Eur Urol on October 30, 2013
The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes (2013) 1.02
Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes (2016) 0.85
Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry. Health Qual Life Outcomes (2014) 0.82
Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. Urol Oncol (2015) 0.77
Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making. J Cancer Res Clin Oncol (2015) 0.76
Times, they are a-changing. Eur Urol (2013) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2011) 5.76
Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA (2013) 4.98
Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol (2002) 3.79
What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol (2000) 3.37
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol (2012) 2.82
Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA (2012) 2.64
Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr (2007) 2.63
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol (2007) 1.84
Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol (2009) 1.72
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol (2008) 1.69
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res (2012) 1.62
Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res (1996) 1.58
Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med (1998) 1.51
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res (2008) 1.43
The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol (2000) 1.41
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol (2006) 1.38
Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res (2010) 1.25
Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer (2003) 1.14
Toward patient-centered drug development in oncology. N Engl J Med (2013) 1.13
Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer (2004) 1.10
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol (2009) 1.00
The quality-of-life impact of prostate cancer treatments. Curr Urol Rep (2010) 0.98
Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol (2003) 0.97
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res (2013) 0.87
Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making. Eur J Cancer (2014) 0.86
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? Crit Rev Oncol Hematol (2015) 0.80
Prostate cancer screening. Investig Clin Urol (2017) 0.75